Adam Frimodig, DO
Family Medicine · Calumet, MINPI 1316381387
Payments from drug & device makers
Across 85 payments — averaging $174.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$14K
- AbbVie$297
- Indivior Inc.$128
- Teva Pharmaceuticals USA, Inc.$125
- GSK$87
- Pfizer$87
- plus $446 from 12 others
What the payments were for
- Speaking & faculty fees$13,35090%
- Travel & lodging$1291%
- Food & beverage$1,3729%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 17 | $13,681 |
| AbbVie(2 entities) | 19 | $297 |
| Indivior Inc. | 5 | $128 |
| Teva Pharmaceuticals USA, Inc. | 8 | $125 |
| GSK | 5 | $87 |
| Pfizer | 5 | $87 |
| Boehringer Ingelheim | 5 | $82 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $75 |
| Novartis | 5 | $72 |
| Braeburn Inc. | 1 | $47 |
| Merck | 2 | $31 |
| Jazz Pharmaceuticals Inc. | 2 | $31 |
| Johnson & Johnson | 2 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $17 |
| Lilly USA, LLC | 1 | $15 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIVITROL$13,597
How this compares
$14,851 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 83 | $61,560 |
| VraylarCariprazine Hcl | 41 | $57,687 |
| TrulicityDulaglutide | 36 | $53,063 |
| EliquisApixaban | 55 | $48,370 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $42,186 |
| OxycontinOxycodone Hcl | 60 | $36,432 |
| Nurtec OdtRimegepant Sulfate | 22 | $31,439 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $28,029 |
| JanuviaSitagliptin Phosphate | 31 | $24,094 |
| OzempicSemaglutide | 24 | $22,502 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 32 | $19,306 |
| VivitrolNaltrexone Microspheres | 11 | $17,760 |
| Xtampza ErOxycodone Myristate | 26 | $17,403 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $16,080 |
| XareltoRivaroxaban | 11 | $13,985 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat, Combivent Respimat, Spiriva Respimat | $82 | $100,925153 claims |
| PfizerEliquis, Nurtec Odt | $87 | $79,80977 claims |
| AbbVieVraylar, Linzess | $297 | $70,85661 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $87 | $55,27886 claims |
| Lilly USA, LLCTrulicity | $15 | $53,06336 claims |
| MerckJanuvia | $31 | $24,09431 claims |
| Novo NordiskOzempic | $14 | $22,50224 claims |
| Alkermes, Inc.Vivitrol | $13,681 | $17,76011 claims |
| Johnson & JohnsonXarelto | $24 | $13,98511 claims |
| Axsome Therapeutics, Inc.Sunosi | $19 | $10,19012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Calumet
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.